Literature DB >> 22463596

The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe.

S Kiwuwa-Muyingo1, A S Walker, H Oja, J Levin, G Miiro, E Katabira, C Kityo, J Hakim, J Todd.   

Abstract

OBJECTIVES: To describe associations between different summaries of adherence in the first year on antiretroviral therapy (ART) and the subsequent risk of mortality, to identify patients at high risk because of early adherence behaviour.
METHODS: We previously described an approach where adherence behaviour at successive clinic visits during the first year on ART was seen as a Markov chain (MC), and the individually estimated transition probabilities between 'good', 'poor' and 'non-response' adherence states were used to classify HIV-infected adults in the DART trial into subgroups with similar behaviour. The impact of this classification and classifications based on traditional 'averaged' measures [mean drug possession ratio (DPR) and self-reported adherence] were compared in terms of their impact on longer-term mortality over the 2-5 years on ART using Cox proportional hazards models.
RESULTS: Of 2960 participants in follow-up after 1 year on ART, 29% had never missed pills in the last month and 11% had 100% DPR throughout the first year. The poorest adherers by self-reported measures were more likely to have only none/primary education (P < 0.01). Being in the poorest adherence subgroup by MC and DPR was independently associated with increased mortality [HR = 1.57 (95% CI 1.02, 2.42); 1.82 (1.32, 2.51) respectively].
CONCLUSIONS: Classification based on dynamic adherence behaviour is associated with mortality independently of DPR. The classifications could be useful in understanding adherence, targeting focused interventions and improving longer-term adherence to therapy.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22463596     DOI: 10.1111/j.1365-3156.2012.02974.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  9 in total

1.  Immunological Response During HAART and Determinants of Current CD4+ T-Cell Count Among HIV/AIDS Patients Attending University of Gondar Referral Hospital, Northwest Ethiopia.

Authors:  Gizachew Ayele Manaye; Dejene Derseh Abateneh; Kindie Mitiku Kebede; Alemayehu Sayih Belay
Journal:  HIV AIDS (Auckl)       Date:  2020-07-31

2.  Role of Education in HIV Clinical Outcomes in a Tuberculosis Endemic Setting.

Authors:  Gabriel M Cohen; Lise Werner; Santhanalakshmi Gengiah; Kogieleum Naidoo
Journal:  J Int Assoc Provid AIDS Care       Date:  2013-05-24

3.  Clinical and immunological outcomes according to adherence to first-line HAART in a urban and rural cohort of HIV-infected patients in Burkina Faso, West Africa.

Authors:  Emanuele Focà; Silvia Odolini; Giorgia Sulis; Stefano Calza; Virginio Pietra; Paola Rodari; Pier Francesco Giorgetti; Alice Noris; Paul Ouedraogo; Jacques Simpore; Salvatore Pignatelli; Francesco Castelli
Journal:  BMC Infect Dis       Date:  2014-03-21       Impact factor: 3.090

4.  Predictors of poor retention on antiretroviral therapy as a major HIV drug resistance early warning indicator in Cameroon: results from a nationwide systematic random sampling.

Authors:  Serge Clotaire Billong; Joseph Fokam; Calixte Ida Penda; Salmon Amadou; David Same Kob; Edson-Joan Billong; Vittorio Colizzi; Alexis Ndjolo; Anne-Cecile Zoung-Kani Bisseck; Jean-Bosco Nfetam Elat
Journal:  BMC Infect Dis       Date:  2016-11-15       Impact factor: 3.090

5.  Social support, disclosure and stigma and the association with non-adherence in the six months after antiretroviral therapy initiation among a cohort of HIV-positive adults in rural KwaZulu-Natal, South Africa.

Authors:  S George; N McGrath
Journal:  AIDS Care       Date:  2018-11-25

6.  High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.

Authors:  Cissy Kityo; Diana M Gibb; Charles F Gilks; Ruth L Goodall; Ivan Mambule; Pontiano Kaleebu; Deenan Pillay; Ronnie Kasirye; Peter Mugyenyi; A Sarah Walker; David T Dunn
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

7.  Dynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART.

Authors:  Sylvia Kiwuwa-Muyingo; Hannu Oja; Ann Walker; Pauliina Ilmonen; Jonathan Levin; Andrew Reid; Peter Mugyenyi; Jim Todd
Journal:  BMC Infect Dis       Date:  2013-08-27       Impact factor: 3.090

8.  Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings.

Authors:  Raphael Z Sangeda; Fausta Mosha; Mattia Prosperi; Said Aboud; Jurgen Vercauteren; Ricardo J Camacho; Eligius F Lyamuya; Eric Van Wijngaerden; Anne-Mieke Vandamme
Journal:  BMC Public Health       Date:  2014-10-04       Impact factor: 3.295

9.  The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.

Authors:  David I Dolling; Ruth L Goodall; Michael Chirara; James Hakim; Peter Nkurunziza; Paula Munderi; David Eram; Dinah Tumukunde; Moira J Spyer; Charles F Gilks; Pontiano Kaleebu; David T Dunn; Deenan Pillay
Journal:  BMC Infect Dis       Date:  2017-02-21       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.